Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 2, 2009, Pages 131-138

  Cho, Hyun Yee ^a,b   Lee, Mija ^a,c   Takei, Hidehiro ^a   Dancer, Jane ^a   Ro, Jae Y ^a   Zhai, Qihui J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Gachon University College of Medicine   (South Korea)

^c Chosun University College of Medicine   (South Korea)

Author keywords

Chondrosarcoma; Chordoid meningioma; Chordoma; D2 40; Immunohistochemistry; Myxopapillary ependymoma

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; EPITHELIAL MEMBRANE ANTIGEN; GALECTIN 3; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOCLONAL ANTIBODY D2-40; NERVE CELL ADHESION MOLECULE; PROTEIN S 100; UVOMORULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHONDROSARCOMA; CHORDOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EPENDYMOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MALIGNANT MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SENSIBILITY;

ANTIBODIES, MONOCLONAL; CHONDROSARCOMA; CHORDOMA; DIAGNOSIS, DIFFERENTIAL; EPENDYMOMA; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MENINGIOMA; MUCIN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 67849128269     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181866a13     Document Type: Article

References (34)

1. Rosai J. Bone joints. In: Rosai J, ed. Rosai and Ackerman's Surgical Pathology. 9th ed. London: Mosby; 2004:2164-2185.
2. Heffelfinger MJ, Dahlin DC, MacCarty CS, et al. Chordomas and cartilaginous tumors at the skull base. Cancer. 1973;32:410-420.
3. Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993;71: 735-740. (Pubitemid 23051375)
4. Berkmen YM, Blatt ES. Cranial and intracranial cartilaginous tumours. Clin Radiol. 1968;19:327-333.
5. Cianfriglia F, Pompili A, Occhipinti E. Intracranial malignant cartilaginous tumours. Report of two cases and review of literature. Acta Neurochir (Wien). 1978;45:163-175. (Pubitemid 9076332)
6. Louis DN, Scheithauer BW, Budka H, et al. Ependymal tumours. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000:71-81.
7. Couce ME, Aker FV, Scheithauer BW. Chordoid meningioma: a clinicopathologic study of 42 cases. Am J Surg Pathol. 2000;24: 899-905. (Pubitemid 30430477)
8. Forsyth PA, Cascino TL, Shaw EG, et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg. 1993;78:741-747. (Pubitemid 23121915)
9. Abenoza P, Sibley RK. Chordoma: an immunohistologic study. Hum Pathol. 1986;17:744-747.
10. Chano T, Ishizawa M, Matsumoto K, et al. The identity of proliferating cells in bone tumors with cartilaginous components: evaluation by double-immunohistochemical staining using proliferating cell nuclear antigen and S-100 protein. Eur J Histochem. 1995;39:21-30.
11. Sell M, Sampaolo S, Di Lorio G, et al. Chordomas: a histological and immunohistochemical study of cases with and without recurrent tumors. Clin Neuropathol. 2004;23:277-285. (Pubitemid 39524558)
12. Sonneland PR, Scheithauer BW, Onofrio BM. Myxopapillary ependymoma. A clinicopathologic and immunocytochemical study of 77 cases. Cancer. 1985;56:883-893. (Pubitemid 15228286)
13. Huse JT, Pasha TL, Zhang PJ. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma. Acta Neuropathol (Berlin). 2007;113:87-94.
14. Meis JM, Giraldo AA. Chordoma. An immunohistochemical study of 20 cases. Arch Pathol Lab Med. 1988;112:553-556.
15. Walker WP, Landas SK, Bromley CM, et al. Immunohistochemical distinction of classic and chondroid chordomas. Mod Pathol. 1991;4:661-666.
16. Rosenberg AE, Nielsen GP, Keel SB, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol. 1999;23:1370-1378.
17. Ishida T, Dorfman HD. Chondroid chordoma versus low-grade chondrosarcoma of the base of the skull: can immunohistochemistry resolve the controversy? J Neurooncol. 1994;18:199-206. (Pubitemid 24209421)
18. Wojno KJ, Hruban RH, Garin-Chesa P, et al. Chondroid chordomas and low-grade chondrosarcomas of the cranial axis. An immunohistochemical analysis of 17 cases. Am J Surg Pathol. 1992;16:1144-1152. (Pubitemid 23004421)
19. Naka T, Oda Y, Iwamoto Y, et al. Immunohistochemical analysis of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM) in chordoma. J Clin Pathol. 2001;54:945-950. (Pubitemid 34032890)
20. Juliao SF, Rand N, Schwartz HS. Galectin-3: a biologic marker and diagnostic aid for chordoma. Clin Orthop Relat Res. 2002;397: 70-75. (Pubitemid 34442017)
21. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209:157-165. (Pubitemid 43805410)
22. Bailey D, Baumal R, Law J, et al. Production of a monoclonal antibody specific for seminomas and dysgerminomas. Proc Natl Acad Sci U S A. 1986;83:5291-5295. (Pubitemid 16051361)
23. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151: 1141-1152. (Pubitemid 27424324)
24. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-394. (Pubitemid 29094089)
25. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
26. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434-440. (Pubitemid 34326952)
27. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer. 1999;80:569-578. (Pubitemid 29213215)
28. Roy S, Chu A, Trojanowski JQ, et al. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol (Berlin). 2005;109:497-502. (Pubitemid 40909194)
29. Shibahara J, Kashima T, Kikuchi Y, et al. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006;448:493-499.
30. Coffin CM, Swanson PE, Wick MR, et al. An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy. Mod Pathol. 1993;6: 531-538.
31. Al-Adnani M, Cannon SR, Flanagan AM. Chordomas do not express CD10 and renal cell carcinoma (RCC) antigen: an immunohistochemical study. Histopathology. 2005;47:535-537. (Pubitemid 41626733)
32. Takei H, Bhattacharjee MB, Adesina AM. Chordoid glioma of the third ventricle: report of a case with cytologic features and utility during intraoperative consultation. Acta Cytol. 2006;50:691-696. (Pubitemid 44777807)
33. Jung TY, Jung S. Third ventricular chordoid glioma with unusual aggressive behavior. Neurol Med Chir (Tokyo). 2006;46:605-608. (Pubitemid 46021215)
34. Brat DJ, Scheithauer BW, Staugaitis SM, et al. Third ventricular chordoid glioma: a distinct clinicopathologic entity. J Neuropathol Exp Neurol. 1998;57:283-290.